Successful therapy of a newborn with Stenotrophomonas maltophilia nosocomial pneumonia with cefiderocol

Janina Trauth; Rahel Schuler; Markus Waitz; Harald Ehrhardt; Moritz Fritzenwanker; Susanne Herold

doi:10.1007/s15010-024-02404-9

Successful therapy of a newborn with Stenotrophomonas maltophilia nosocomial pneumonia with cefiderocol

Infection. 2024 Oct 7. doi: 10.1007/s15010-024-02404-9. Online ahead of print.

Authors

Janina Trauth¹, Rahel Schuler², Markus Waitz², Harald Ehrhardt^{2

3}, Moritz Fritzenwanker⁴, Susanne Herold⁵

Affiliations

¹ Department of Medicine V - Internal Medicine, Infectious Diseases & Infection Control, Justus- Liebig-University, Giessen, Germany. [email protected].
² Department of General Pediatrics and Neonatology, Justus Liebig University, Giessen, Germany.
³ Division of Neonatology and Pediatric Intensive Care Medicine, Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.
⁴ Institute of Medical Microbiology, Justus Liebig University Giessen, Giessen, Germany.
⁵ Department of Medicine V - Internal Medicine, Infectious Diseases & Infection Control, Justus- Liebig-University, Giessen, Germany.

PMID: 39373949
DOI: 10.1007/s15010-024-02404-9

Abstract

Cefiderocol is a new siderophore-beta-lactam antibiotic used for the treatment of severe multidrug-resistant infections like sepsis, hospital-acquired and ventilator-associated pneumonia in adults, but there are only single reports on its use in the neonatal population. We describe the successful cefiderocol treatment of a newborn with pneumogenic sepsis due to Stenotrophomonas maltophilia.

Keywords: Stenotrophomonas maltophilia; Cefiderocol; Multi drug resistance; Neonate; Pneumogenic sepsis.